Pembrolizumab
Hormone Receptor-Positive Breast Cancer
Explore 112 assets in Hormone Receptor-Positive Breast Cancer →Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Aminex Therapeutics, Inc.
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07287917CT.gov Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06545331CT.gov Study of XB010 in Subjects With Solid Tumors | — | Recruiting | — | — | — |
NCT05020860CT.gov Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer | — | Recruiting | — | — | — |
NCT05286437CT.gov Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole | — | Recruiting | — | — | — |
NCT05234606CT.gov A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors | — | Withdrawn | — | — | — |
NCT05194072CT.gov A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors | — | Terminated | — | — | — |
NCT04443348CT.gov Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD) | — | Active Not Recruiting | — | — | — |
NCT04585750CT.gov The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | — | Recruiting | — | — | — |
NCT04448886CT.gov Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hormone Receptor-Positive Breast Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pembrolizumab (this asset) | Aminex Therapeutics, Inc. | P2 | BB · 64 |
| Everolimus | Ellipses Pharma | P4 | BBB |
| Exemestane | Fujian Cancer Hospital | P4 | BBB |
| Anastrozole | University of Illinois at Chicago | P4 | BBB |
| Ribociclib | BeOne Medicines | P4 | BBB |
| Palbociclib | BeOne Medicines | P3 | BBB |
| Abemaciclib | BeOne Medicines | P4 | BBB |
| Capecitabine | Kristina A. Fanucci | P4 | BBB |
| Trastuzumab | Tianjin Medical University Cancer Institute and Hospital | P3 | BB |
+42 more in the Hormone Receptor-Positive Breast Cancer cohort
Other indications for Pembrolizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Her2-Receptor Negative Breast Cancer | — | P2 | BBB · 72 |
| Estrogen-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
| Progesterone-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pembrolizumab in Hormone Receptor-Positive Breast Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pembrolizumab-hormone-receptor-positive-breast-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →